P1.088. Reduced-Dose Cisplatin-Based Preoperative Chemotherapy vs. Surgery Alone for Cisplatin-Unfit Esophageal Cancer: A Multicenter Retrospective Study in Japan

Clicks: 27
ID: 325903
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #23 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Based on the results of the JCOG1109 trial, preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil followed by radical resection is the standard of care for resectable esophageal squamous cell carcinoma (ESCC). However, a standard strategy has not been established for patients excluded from JCOG1109, such as those aged 76 or older or those with organ dysfunction. This study aimed to compare the efficacy and safety of preoperative reduced-dose cisplatin plus fluorouracil (RD-CF) versus surgery alone in patients with resectable ESCC who were ineligible for standard-dose cisplatin. Methods We retrospectively reviewed data from 25 institutions for resectable ESCC patients who received either RD-CF or surgery alone between January 2017 and December 2021. The inclusion criteria were as follows: (1) age ≥18 years; (2) ECOG PS 0-2; (3) Stage II-III (Japanese Classification of Esophageal Cancer, 12th Edition); (4) age ≥75 years, creatinine clearance (CCr) <60 ml/min, or cardiac dysfunction; and (5) initial cisplatin dose reduced to <65 mg/m2. The primary endpoint was overall survival (OS), and the secondary endpoints included relapse-free survival (RFS), radical resection rate, pathological response, and adverse events. Propensity score matching (PSM) was performed using covariates, including age, sex, CCr, neutrophil-to-lymphocyte ratio, cardiac dysfunction, and cT/N/M stages. Results Of the 406 registered cases, 140 in the surgery-alone group and 90 in the RD-CF group were analyzed. In the pre-PSM cohort, the median age was 79 vs. 76 years, and the median CCr was 55.2 vs. 50.7 ml/min. In the RD-CF group, the median initial doses were 60.7 mg/m2 for cisplatin and 786.8 mg/m2 for fluorouracil. Surgery was performed in 100% of the surgery-alone group and 93.3% of the RD-CF group. A pathological response was observed in 18.9% of patients in the RD-CF group. Multivariable analysis showed no significant differences in survival between the groups (RFS: hazard ratio [HR] 0.75, 95% confidence interval [CI] 0.44–1.27; OS: HR 0.70, 95% CI 0.42–1.16). After PSM, all standardized differences were <20%. Post-PSM analysis also demonstrated no significant differences in survival (RFS: HR 1.01, 95% CI 0.52–1.97; OS: HR 1.02, 95% CI 0.51–2.02). Conclusion For patients with resectable ESCC who are ineligible for standard-dose cisplatin due to advanced age, renal impairment, or cardiac dysfunction, the clinical benefit of preoperative RD-CF may be limited compared to that of surgery alone.
Reference Key
openalex_W7203996871 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shota Fukuoka, Taisuke Hosokai, Motoo Nomura, Toru Kadono, Akitoshi Hakoda, Shun Yamamoto, Shigenori Kadowaki, Takeshi Yamashita, Kunihiro Fushiki, Kazuhiro Shiraishi, Yuta Sato, Kohei Kanamori, Yohei Ozawa, Atsushi Takeno, Masaaki Iwatsuki, Yuta Ibuki, Yusuke Amanuma, Kazuma Sato, Ryoma Haneda, Hisahiro Matsubara, Takeo Bamba, Hiroo Hiratsuka, Hisashi Fujiwara, Takashi Ogata, Yoshito Komatsu, Hiroshi Ichikawa, Takashi Ohta, Hiroaki Nagano, Satoru Matsuda, Hiroya Takeuchi, Ken Kato
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.236
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.236/70760571/doag077.236.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.